Emtricitabine (Emtriva) vs Rilpivirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Emtricitabine (Emtriva)

Marketed by Gilead Sciences and partners

Approved in HIVsmall molecule
Partial signal

NCT00112047 · Phase 3 · completed

The trial randomized 517 participants to an active comparator, but treatment was open-label rather than double-blinded. Its hard clinical virologic endpoint was met: 84.4% versus 72.8% achieved confirmed HIV-1 RNA below 400 copies/mL at week 48 (p=0.002; 95% CI for the difference, 4.3% to 18.6%), supporting non-inferiority and a favorable result, but the lack of blinding limits the evidence strength.

Next expected readout: June 2029 · NCT07792096 (registry estimate)

Reported efficacy

Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants (met)

Result source: NCT00112047

Rilpivirine · Edurant

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00540449 · Phase 3 · completed

This was a large (690-participant), randomized, quadruple-blinded, active-controlled (efavirenz) phase 3 trial with a hard clinical endpoint (confirmed viral load <50 copies/mL). The pre-specified non-inferiority margin was clearly met, with the confidence interval for the treatment difference falling entirely within the allowed -12% boundary, so rilpivirine was shown to be as effective as efavirenz on the primary measure despite a somewhat higher rate of virologic failure and resistance emergence as a secondary finding.

Next expected readout: December 2028 · NCT07637877 (registry estimate)

Reported efficacy

Number of Participants With Virological Response (Intent-to-Treat - Time to Loss of Virologic Response [TLOVR], <50 Copies/ml) at Week 48: Week 48 TLOVR virologic response: 287/346 rilpivirine vs 285/344 efavirenz; adjusted difference -0.4% (95% CI -5.9% to 5.2%), p<0.0001; non-inferiority margin -12%. (met)

Result source: NCT00540449

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmtricitabine (Emtriva)Rilpivirine
HIV-1 RNA below 50 copies/mL (week 48)—Not posted · NCT0000241694% vs 94%vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
12 other results
  • 95% vs 96% wk 48 · n 252 · Phase 3 · primary NCT02429791
  • 93.7% vs 93.9% wk 48 · n 316 · Phase 3 · primary NCT02345252
  • 90% vs 92% wk 48 · n 438 · Phase 3 · primary NCT02345226
  • 85.8% vs 81.6% wk 48 · n 394 · Phase 3 · primary NCT01309243
  • 93.7% vs 89.9% wk 24 · n 317 · Phase 3 · primary NCT01252940
  • 97% vs 98% DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 89.2% vs 88.5% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 85.2% vs 85.1% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 77.9% vs 72.4% wk 96 · n 394 · Phase 3 · secondary NCT01309243
  • 93.9% vs 96.2% wk 48 · n 213 · Phase 3 · secondary NCT01709084
  • 89.3% vs 92.1% wk 48 · n 317 · Phase 3 · secondary NCT01252940
  • 98% vs 96% wk 24 · n 252 · Phase 3 · secondary NCT02429791
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT000024160.6% vs 1%vs FTC/RPV/TDFwk 96 · n 316NCT02345252
3 other results
  • 0.7% vs 0.9% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 0.6% vs 0% wk 48 · n 316 · Phase 3 · secondary NCT02345252
  • 1.1% vs 0.9% wk 48 · n 438 · Phase 3 · secondary NCT02345226
CD4 count, change (week 48)—Not posted · NCT0000241628 vs 18.4vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
14 other results
  • 42 vs 42.4 DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 12 vs 16 wk 96 · n 283 · Phase 3 · secondary NCT02345252
  • 12 vs 6 wk 96 · n 370 · Phase 3 · secondary NCT02345226
  • 278 vs 259 wk 96 · n 327 · Phase 3 · secondary NCT01309243
  • 32.3 vs 41.8 wk 48 · n 252 · Phase 3 · secondary NCT02429791
  • 9 vs -1 wk 48 · n 296 · Phase 3 · secondary NCT02345252
  • 23 vs 12 wk 48 · n 390 · Phase 3 · secondary NCT02345226
  • 10 vs -7 wk 48 · n 287 · Phase 3 · secondary NCT01252940
  • 200 vs 191 wk 48 · n 357 · Phase 3 · secondary NCT01309243
  • 16.2 vs 47.4 wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 20 vs 32 wk 24 · n 298 · Phase 3 · secondary NCT01252940
  • 145.9 vs 159.8 25 mg · wk 96 · n 93 · Phase 2 · secondary NCT00110305
  • 158.9 vs 159.8 150 mg · wk 96 · n 91 · Phase 2 · secondary NCT00110305
  • 172 vs 159.8 75 mg · wk 96 · n 95 · Phase 2 · secondary NCT00110305

HIV-1 RNA below 50 copies/mL (week 48)

Emtricitabine (Emtriva)
—Not posted · NCT00002416
Rilpivirine
94% vs 94%vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
12 other results
  • 95% vs 96% wk 48 · n 252 · Phase 3 · primary NCT02429791
  • 93.7% vs 93.9% wk 48 · n 316 · Phase 3 · primary NCT02345252
  • 90% vs 92% wk 48 · n 438 · Phase 3 · primary NCT02345226
  • 85.8% vs 81.6% wk 48 · n 394 · Phase 3 · primary NCT01309243
  • 93.7% vs 89.9% wk 24 · n 317 · Phase 3 · primary NCT01252940
  • 97% vs 98% DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 89.2% vs 88.5% wk 96 · n 316 · Phase 3 · secondary NCT02345252
  • 85.2% vs 85.1% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 77.9% vs 72.4% wk 96 · n 394 · Phase 3 · secondary NCT01309243
  • 93.9% vs 96.2% wk 48 · n 213 · Phase 3 · secondary NCT01709084
  • 89.3% vs 92.1% wk 48 · n 317 · Phase 3 · secondary NCT01252940
  • 98% vs 96% wk 24 · n 252 · Phase 3 · secondary NCT02429791

HIV-1 RNA 50 copies/mL or more (week 48)

Emtricitabine (Emtriva)
—Not posted · NCT00002416
Rilpivirine
0.6% vs 1%vs FTC/RPV/TDFwk 96 · n 316NCT02345252
3 other results
  • 0.7% vs 0.9% wk 96 · n 438 · Phase 3 · secondary NCT02345226
  • 0.6% vs 0% wk 48 · n 316 · Phase 3 · secondary NCT02345252
  • 1.1% vs 0.9% wk 48 · n 438 · Phase 3 · secondary NCT02345226

CD4 count, change (week 48)

Emtricitabine (Emtriva)
—Not posted · NCT00002416
Rilpivirine
28 vs 18.4vs CARDTG 50 mg + RPV 25 mg · wk 48 · n 261NCT02422797
14 other results
  • 42 vs 42.4 DTG 50 mg + RPV 25 mg · wk 24 · n 261 · Phase 3 · secondary NCT02422797
  • 12 vs 16 wk 96 · n 283 · Phase 3 · secondary NCT02345252
  • 12 vs 6 wk 96 · n 370 · Phase 3 · secondary NCT02345226
  • 278 vs 259 wk 96 · n 327 · Phase 3 · secondary NCT01309243
  • 32.3 vs 41.8 wk 48 · n 252 · Phase 3 · secondary NCT02429791
  • 9 vs -1 wk 48 · n 296 · Phase 3 · secondary NCT02345252
  • 23 vs 12 wk 48 · n 390 · Phase 3 · secondary NCT02345226
  • 10 vs -7 wk 48 · n 287 · Phase 3 · secondary NCT01252940
  • 200 vs 191 wk 48 · n 357 · Phase 3 · secondary NCT01309243
  • 16.2 vs 47.4 wk 24 · n 252 · Phase 3 · secondary NCT02429791
  • 20 vs 32 wk 24 · n 298 · Phase 3 · secondary NCT01252940
  • 145.9 vs 159.8 25 mg · wk 96 · n 93 · Phase 2 · secondary NCT00110305
  • 158.9 vs 159.8 150 mg · wk 96 · n 91 · Phase 2 · secondary NCT00110305
  • 172 vs 159.8 75 mg · wk 96 · n 95 · Phase 2 · secondary NCT00110305
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Emtricitabine (Emtriva)
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants NCT00112047 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Emtricitabine (Emtriva): 0 of 4 rows · Rilpivirine: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRilpivirine
Dropout rate
24.3%a
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
20%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
5.2%DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
6.1%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01709084 · Phase 3 · registry result, not featured evidence
22.3%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
25.2%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
12.7%FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
15.7%FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
8.1%
NCT01252940 · Phase 3 · registry result, not featured evidence
21%
NCT01309243 · Phase 3 · registry result, not featured evidence
0%
NCT04012931 · Phase 2 · registry result, not featured evidence
30.6%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
40%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
33.3%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
12.1%
NCT02165202 · Phase 2 · registry result, not featured evidence
4%
NCT01286740 · Phase 2 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
7.1%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
3.5%a
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
5.3%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
2.4%DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
4.2%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT01709084 · Phase 3 · registry result, not featured evidence
3%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
2.5%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
0.6%FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
1.1%FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
—Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
0.9%
NCT01252940 · Phase 3 · registry result, not featured evidence
3%
NCT01309243 · Phase 3 · registry result, not featured evidence
—
NCT04012931 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
—
NCT02165202 · Phase 2 · registry result, not featured evidence
—
NCT01286740 · Phase 2 · registry result, not featured evidence
—50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
—
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
11.6%a
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 32 more results
9.4%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
—DTG + RPV
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
3.2%DTG + RPV (Continuation Phase)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
13.5%DTG + RPV (Early + Late Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
4%DTG + RPV (Early Switch)
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
—DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
5.8%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
14.6%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.3%DTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
7.5%
NCT01709084 · Phase 3 · registry result, not featured evidence
4.4%RPV (TMC278-TiDP6-C209 [C209] and
NCT01266902 · Phase 3 · registry result, not featured evidence
7.6%Rilpivirine (RPV) (TMC278-C204 [C2
NCT01266902 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF
NCT02345252 · Phase 3 · registry result, not featured evidence
11.4%FTC/RPV/TAF (Double-Blind Phase)
NCT02345252 · Phase 3 · registry result, not featured evidence
5.3%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
0%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345252 · Phase 3 · registry result, not featured evidence
—FTC/RPV/TAF
NCT02345226 · Phase 3 · registry result, not featured evidence
12.3%FTC/RPV/TAF (Double-Blind Phase)
NCT02345226 · Phase 3 · registry result, not featured evidence
4.8%Open-Label FTC/RPV/TAF From EFV/FT
NCT02345226 · Phase 3 · registry result, not featured evidence
0%Open-Label FTC/RPV/TAF From FTC/RP
NCT02345226 · Phase 3 · registry result, not featured evidence
6.6%
NCT01252940 · Phase 3 · registry result, not featured evidence
9.1%
NCT01309243 · Phase 3 · registry result, not featured evidence
0%
NCT04012931 · Phase 2 · registry result, not featured evidence
16.7%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
0%12.5 mg
NCT00799864 · Phase 2 · registry result, not featured evidence
4.4%
NCT02165202 · Phase 2 · registry result, not featured evidence
2%
NCT01286740 · Phase 2 · registry result, not featured evidence
0%50mg/25mg
NCT03984838 · Phase 1 · registry result, not featured evidence
0%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
upper respiratory tract infection 15.3%
diarrhoea 14.7%
headache 14.5%
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 28 more results
headache 17.9%
nausea 16.8%
nasopharyngitis 14.7%
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
arthralgia 0%
back pain 0%
bronchitis 0%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 20.6%
headache 14.7%
diarrhoea 13.9%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 10.7%
headache 9.5%
diarrhoea 8.7%
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
arthralgia 0%
asthenia 0%
back pain 0%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
nasopharyngitis 18.4%
upper respiratory tract infection 14.2%
bronchitis 10.7%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
DTG 50 mg + RPV 25 mg
nasopharyngitis 8%
upper respiratory tract infection 7.3%
arthralgia 6.5%
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 29.6%
headache 17.8%
urinary tract infection 13.6%
NCT01709084 · Phase 3 · registry result, not featured evidence
pregnancy 1.9%
headache 1.1%
alanine aminotransferase increased 0.8%
NCT01266902 · Phase 3 · registry result, not featured evidence
facial wasting 1.7%
hepatitis c 1.7%
hypertension 1.7%
NCT01266902 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.5%
upper respiratory tract infection 14.9%
diarrhoea 10.8%
NCT02345252 · Phase 3 · registry result, not featured evidence
back pain 10.5%
conjunctivitis allergic 10.5%
cough 10.5%
NCT02345252 · Phase 3 · registry result, not featured evidence
cough 17.6%
nasopharyngitis 17.6%
pyrexia 17.6%
NCT02345252 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 16.9%
nasopharyngitis 11.6%
cough 10.3%
NCT02345226 · Phase 3 · registry result, not featured evidence
cough 9.5%
diarrhoea 9.5%
eczema 9.5%
NCT02345226 · Phase 3 · registry result, not featured evidence
rhinitis 16%
nasopharyngitis 12%
bronchitis 8%
NCT02345226 · Phase 3 · registry result, not featured evidence
nasopharyngitis 11%
diarrhoea 10.7%
headache 9.8%
NCT01252940 · Phase 3 · registry result, not featured evidence
diarrhoea 17.5%
nausea 16.5%
upper respiratory tract infection 14.5%
NCT01309243 · Phase 3 · registry result, not featured evidence
vomiting 15.4%
alanine aminotransferase increased 11.5%
abdominal pain 7.7%
NCT04012931 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 55.6%
influenza 41.7%
cough 27.8%
NCT00799864 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 60%
toothache 40%
alanine aminotransferase increased 20%
NCT00799864 · Phase 2 · registry result, not featured evidence
25 mg
upper respiratory tract infection 55.6%
decreased appetite 22.2%
diarrhoea 22.2%
NCT00799864 · Phase 2 · registry result, not featured evidence
15 mg
upper respiratory tract infection 100%
anaemia 50%
dermatitis atopic 50%
NCT00799864 · Phase 2 · registry result, not featured evidence
12.5 mg
upper respiratory tract infection 100%
cough 50%
lower respiratory tract infection 50%
NCT00799864 · Phase 2 · registry result, not featured evidence
injection site pain 75% (placebo 40.5%)
injection site pruritus 36.3% (placebo 11.9%)
injection site swelling 36.3% (placebo 7.1%)
NCT02165202 · Phase 2 · registry result, not featured evidence
diarrhoea 16.3%
upper respiratory tract infection 14.3%
insomnia 12.2%
NCT01286740 · Phase 2 · registry result, not featured evidence
50mg/25mg
headache 6.3%
vessel puncture site bruise 6.3%
vomiting 6.3%
NCT03984838 · Phase 1 · registry result, not featured evidence
insomnia 23.1%
NCT01562886 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 31 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Rilpivirine

Virologic Response Rate Lt50 Copies 82.9% (n=346) vs 82.8% (n=344) Efavirenz @ 48wk
responder rate · % of participants
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 287 Participants as posted
show 2 more results
76% (n=346) vs 78.8% (n=344) Efavirenz @ 96wk*
Responder
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 263 Participants as posted
95% (n=258) vs 96.3% (n=271) Efavirenz*
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 245 Participants as posted
Virologic Response Rate Lt50 Copies 82.4% (n=346) vs 81.7% (n=344) Efavirenz @ 48wk
responder rate · % of participants
Virologic Response HIV RNA <50 copies/mL at Wk 48
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 285 Participants as posted
Virologic Response Rate Lt50 Copies 76.6% (n=346) vs 77.9% (n=344) Efavirenz @ 96wk
responder rate · % of participants
Virologic Response, <50 copies/ml
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 265 Participants as posted
Virologic Response Rate Lt400 Copies 85.8% (n=346) vs 85.2% (n=344) Efavirenz @ 48wk
responder rate · % of participants
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 297 Participants as posted
show 1 more result
78.9% (n=346) vs 80.8% (n=344) Efavirenz @ 96wk*
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 273 Participants as posted
CD4+ 195.5 vs 181.6 Efavirenz cells/uL @ 48wk
absolute change · cells/uL
Absolute cell count, Week 48
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
188.6 vs 170.7 Efavirenz cells/uL @ 48wk
Absolute cell count, Week 48
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
CD4+ 220.7 vs 226.7 Efavirenz cells/uL @ 96wk
absolute change · cells/uL
Absolute cell count, Week 96
NCT00540449 · Phase 3 · monotherapy · HIV · phase 3
show 1 more result
234.5 vs 212 Efavirenz cells/uL @ 96wk
Absolute cell count, Week 96
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3
Virological Response 50 Copies TLOVR 85.6% (n=340) vs 81.7% (n=338) Efavirenz @ 48wk
event count · % of participants
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 291 Participants as posted
show 1 more result
79.1% (n=340) vs 76.3% (n=338) Efavirenz @ 96wk*
Responder
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 269 Participants as posted
Virological Response 50 Copies Snapshot 82.6% (n=340) vs 78.4% (n=338) Efavirenz @ 48wk
event count · % of participants
Virologic Response (<50 copies/mL)
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 281 Participants as posted
show 1 more result
76.2% (n=340) vs 75.1% (n=338) Efavirenz @ 96wk*
Virologic response (<50 copies/mL)
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 259 Participants as posted
Virological Response 400 Copies TLOVR 88.2% (n=340) vs 84.6% (n=338) Efavirenz @ 48wk
event count · % of participants
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 300 Participants as posted
show 1 more result
83.2% (n=340) vs 79.9% (n=338) Efavirenz @ 96wk*
NCT00543725 · Phase 3 · monotherapy · HIV · phase 3 · converted to % from 283 Participants as posted
HIV-1 RNA Less Than 50 Copies 94% (n=261) vs 94% (n=255) CAR @ 48wkDTG 50 mg + RPV 25 mg
responder rate · % of participants
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
show 12 more results
97% (n=261) vs 98% (n=255) CAR @ 24wkDTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
95% (n=252) vs 96% (n=256) Current Antiretroviral Regimen (CAR) @ 48wk
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
98% (n=252) vs 96% (n=256) Current Antiretroviral Regimen (CAR) @ 24wk
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
93.9% (n=213) vs 96.2% (n=211) TDF/FTC/EFV @ 48wk
NCT01709084 · Phase 3 · registry result, not featured evidence
93.7% (n=316) vs 93.9% (n=313) FTC/RPV/TDF @ 48wk
NCT02345252 · Phase 3 · registry result, not featured evidence
89.2% (n=316) vs 88.5% (n=313) FTC/RPV/TDF @ 96wk
NCT02345252 · Phase 3 · registry result, not featured evidence
90% (n=438) vs 92% (n=437) EFV/FTC/TDF @ 48wk
NCT02345226 · Phase 3 · registry result, not featured evidence
85.2% (n=438) vs 85.1% (n=437) EFV/FTC/TDF @ 96wk
NCT02345226 · Phase 3 · registry result, not featured evidence
93.7% (n=317) vs 89.9% (n=159) SBR @ 24wk
NCT01252940 · Phase 3 · registry result, not featured evidence
89.3% (n=317) vs 92.1% (n=152) SBR @ 48wk
NCT01252940 · Phase 3 · registry result, not featured evidence
85.8% (n=394) vs 81.6% (n=392) EFV/FTC/TDF @ 48wk
NCT01309243 · Phase 3 · registry result, not featured evidence
77.9% (n=394) vs 72.4% (n=392) EFV/FTC/TDF @ 96wk
NCT01309243 · Phase 3 · registry result, not featured evidence
CD4+ 145.9 vs 159.8 Efavirenz cells/uL @ 96wk25 mg
absolute change · cells/uL
NCT00110305 · Phase 2 · registry result, not featured evidence
show 14 more results
158.9 vs 159.8 Efavirenz cells/uL @ 96wk150 mg
NCT00110305 · Phase 2 · registry result, not featured evidence
172 vs 159.8 Efavirenz cells/uL @ 96wk75 mg
NCT00110305 · Phase 2 · registry result, not featured evidence
42 vs 42.4 CAR cells/uL @ 24wkDTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
28 vs 18.4 CAR cells/uL @ 48wkDTG 50 mg + RPV 25 mg
NCT02422797 · Phase 3 · registry result, not featured evidence · combination
16.2 vs 47.4 Current Antiretroviral Regimen (CAR) cells/uL @ 24wk
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
32.3 vs 41.8 Current Antiretroviral Regimen (CAR) cells/uL @ 48wk
NCT02429791 · Phase 3 · registry result, not featured evidence · combination
9 vs -1 FTC/RPV/TDF cells/uL @ 48wk
NCT02345252 · Phase 3 · registry result, not featured evidence
12 vs 16 FTC/RPV/TDF cells/uL @ 96wk
NCT02345252 · Phase 3 · registry result, not featured evidence
23 vs 12 EFV/FTC/TDF cells/uL @ 48wk
NCT02345226 · Phase 3 · registry result, not featured evidence
12 vs 6 EFV/FTC/TDF cells/uL @ 96wk
NCT02345226 · Phase 3 · registry result, not featured evidence
20 vs 32 SBR cells/uL @ 24wk
NCT01252940 · Phase 3 · registry result, not featured evidence
10 vs -7 SBR cells/uL @ 48wk
NCT01252940 · Phase 3 · registry result, not featured evidence
200 vs 191 EFV/FTC/TDF cells/uL @ 48wk
NCT01309243 · Phase 3 · registry result, not featured evidence
278 vs 259 EFV/FTC/TDF cells/uL @ 96wk
NCT01309243 · Phase 3 · registry result, not featured evidence
HIVTSQc 0 vs 0 Current Antiretroviral Regimen (CAR) score @ 4wk
absolute change · score
Total score, Week 4
NCT02429791 · Phase 3 · registry result, not featured evidence · combination

+ 22 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine (Emtriva)'s landscape · Rilpivirine's landscape